Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.

PURPOSE: Prostate specific antigen velocity has been proposed as a marker to aid in prostate cancer detection. We determined whether prostate specific antigen velocity could predict repeat biopsy results in men with persistently increased prostate specific antigen after initial negative biopsy. MAT...

Full description

Bibliographic Details
Main Authors:	Vickers, A, Wolters, T, Savage, C, Cronin, A, O'Brien, M, Roobol, M, Aus, G, Scardino, P, Hugosson, J, Schröder, F, Lilja, H
Format:	Journal article
Language:	English
Published:	2010

Similar Items

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
by: Vickers, A, et al.
Published: (2009)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
by: Vickers, A, et al.
Published: (2010)

Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening.
by: Zackrisson, B, et al.
Published: (2003)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden.
by: Vickers, A, et al.
Published: (2008)

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.
by: Vickers, A, et al.
Published: (2010)

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.
by: Vickers, A, et al.
Published: (2009)

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
by: Vickers, A, et al.
Published: (2010)

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands.
by: Gupta, A, et al.
Published: (2010)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
by: Vickers, A, et al.
Published: (2010)

Can PSA velocity predict risk of death in men with prostate cancer?
by: Lilja, H, et al.
Published: (2007)

Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
by: Ankerst, D, et al.
Published: (2014)

Increase in percent free prostate-specific antigen in men with chronic kidney disease.
by: Bruun, L, et al.
Published: (2009)

Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening.
by: Savage, C, et al.
Published: (2010)

Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees.
by: Bergdahl, A, et al.
Published: (2009)

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.
by: Roobol, M, et al.
Published: (2012)

Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.
by: Carlsson, S, et al.
Published: (2012)

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio.
by: Aus, G, et al.
Published: (2004)

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
by: Vickers, A, et al.
Published: (2011)

Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
by: Ankerst, D, et al.
Published: (2012)

Screening for prostate cancer.
by: Carlsson, S, et al.
Published: (2012)

Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
by: Christensson, A, et al.
Published: (2011)

Screening for prostate cancer: To the editor
by: Carlsson, S, et al.
Published: (2012)

Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
by: Hugosson, J, et al.
Published: (2004)

Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.
by: Klein, R, et al.
Published: (2012)

Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
by: Hugosson, J, et al.
Published: (2003)

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study.
by: Ulmert, D, et al.
Published: (2008)

Five genetic variants associated with prostate cancer.
by: Vickers, A, et al.
Published: (2008)

A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France.
by: Benchikh, A, et al.
Published: (2010)

Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively.
by: O'Brien, M, et al.
Published: (2011)

Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
by: Aus, G, et al.
Published: (2003)

Screening for prostate cancer: early detection or overdetection?
by: Vickers, A, et al.
Published: (2012)

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.
by: Hugosson, J, et al.
Published: (2003)

Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study.
by: Aus, G, et al.
Published: (2005)

The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable.
by: Zackrisson, B, et al.
Published: (2004)

Evolution of free, complexed, and total serum prostate-specific antigen and their ratios during 1 year of follow-up of men with febrile urinary tract infection.
by: Zackrisson, B, et al.
Published: (2003)

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
by: Vickers, A, et al.
Published: (2010)

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study
by: Vickers, A, et al.
Published: (2010)

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
by: O'Brien, M, et al.
Published: (2009)

Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated?
by: Vickers, A, et al.
Published: (2010)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
by: Lilja, H, et al.
Published: (2008)